In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genentech pays $35mm up front for Actelion's Tracleer

Executive Summary

Genentech agreed to pay (uf)$35mm up front for the right to co-promote Actelion's pulmonary hypertension and chronic heart failure drug Tracleer (bosentan), in the US, upon the drug's approval for both indications.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Intra-Biotech Deal

Related Companies

UsernamePublicRestriction

Register